15.5 Common Dermatologic Disorders in Women Across the Lifespan
Key Takeaways
Adult female acne vulgaris characteristically presents with inflammatory papules, pustules, and deep painful nodules along the lower face, jawline, chin, and neck with premenstrual exacerbations, driven by follicular hyperkeratinization, Cutibacterium acnes colonization, and androgen sensitivity.
Stepwise pharmacotherapy includes topical retinoids and benzoyl peroxide, combined oral contraceptives, oral spironolactone (50–100 mg daily; requires potassium monitoring and effective contraception to prevent feminization of male fetus), and oral isotretinoin (strictly teratogenic, requiring iPLEDGE registry compliance with two negative pregnancy tests and two concurrent contraceptive methods).
Rosacea is distinguished from acne by the absence of comedones, featuring central facial erythema, telangiectasias, and inflammatory papules triggered by UV light, alcohol, and spicy foods; managed with trigger avoidance, broad-spectrum sunscreen, topical metronidazole, ivermectin, or azelaic acid.
Specific dermatoses of pregnancy require precise differentiation: Pruritic Urticarial Papules and Plaques of Pregnancy (PUPPP) arises in abdominal striae with periumbilical sparing in late third-trimester primigravidas and carries no fetal risk, whereas Intrahepatic Cholestasis of Pregnancy (ICP) presents with severe nocturnal pruritus on palms and soles without primary rash, elevated total bile acids (≥10 µmol/L), and severe risks of sudden intrauterine demise and preterm birth.
Melanoma is a leading malignancy in reproductive-age and pregnant women; screening utilizes the ABCDE criteria (Asymmetry, Border, Color, Diameter >6 mm, Evolving), and any clinically suspicious pigmented lesion requires urgent full-thickness excisional biopsy (not superficial shave) for accurate Breslow depth staging.
Acne Vulgaris in Adult Women: Pathogenesis & Presentation
Acne vulgaris affects over 30% to 50% of women in their 20s and 30s. Four pathogenic factors drive lesion development:
- Follicular Hyperkeratinization: Abnormal desquamation of ductal keratinocytes within the pilosebaceous infundibulum creates the microscopic precursor of all acne lesions—the microcomedone.
- Androgen-Driven Sebum Production: Androgens stimulate sebocyte hypertrophy and excess sebum secretion.
- Cutibacterium acnes Proliferation: Cutibacterium acnes proliferates within the lipid-rich microenvironment of plugged follicles.
- Inflammatory Cascades: C. acnes hydrolyzes sebum triglycerides into free fatty acids and activates Toll-like receptor 2 (TLR2), triggering neutrophil chemotaxis and follicular rupture.
Adult Female Phenotype (The "U-Zone" Pattern)
- Distribution: Concentrated along the lower third of the face, mandibular jawline, chin, and anterior neck (the "U-zone").
- Morphology: Deep-seated, tender inflammatory papules, pustules, and nodulocystic lesions, often with sparse superficial comedones.
- Premenstrual Flares: Over 70% of women experience flares 7 to 10 days prior to menses, coinciding with the luteal drop in estrogen relative to androgens.
- Hyperandrogenism Screening: Adult-onset or treatment-resistant acne warrants evaluation for Polycystic Ovary Syndrome (PCOS), congenital adrenal hyperplasia, or adrenal/ovarian tumors if accompanied by hirsutism (Ferriman-Gallwey score >8), oligomenorrhea, androgenic alopecia, or acanthosis nigricans.
Stepwise Pharmacotherapy: Topical Retinoids, Spironolactone & Isotretinoin iPLEDGE
1. Topical Regimens
- Topical Retinoids (Tretinoin 0.025%–0.1%, Adapalene 0.1%–0.3%, Tazarotene): Foundational first-line therapy; normalizes follicular desquamation and prevents microcomedones. Apply a pea-sized amount at bedtime. Adverse effects: erythema, peeling, photosensitivity. Strictly contraindicated in pregnancy.
- Benzoyl Peroxide (BPO 2.5%–5%): Bactericidal via reactive oxygen species; zero bacterial resistance develops. Co-prescribe with topical clindamycin to prevent antibiotic resistance.
- Topical Clindamycin (1%): Anti-inflammatory antibiotic; always combine with BPO.
- Topical Azelaic Acid (15%–20%): Comedolytic, antimicrobial, and inhibits tyrosinase (reduces post-inflammatory hyperpigmentation); pregnancy-safe (Category B).
- Topical Dapsone (5%–7.5%): Anti-inflammatory sulfone effective for female inflammatory acne.
2. Systemic Hormonal Therapies
- Combined Oral Contraceptives (COCs): FDA-approved formulations contain ethinyl estradiol with norgestimate, norethindrone acetate, or drospirenone. Estrogen increases Sex Hormone-Binding Globulin (SHBG), reducing bioavailable free testosterone, while progestins suppress ovarian androgen production.
- Oral Spironolactone (50 to 100 mg daily, titrated to 200 mg): Synthetic aldosterone antagonist and competitive androgen receptor blocker that inhibits 5-alpha reductase.
- Safety & Monitoring: Baseline potassium; monitor periodically in women >45 years or those on concurrent RAAS inhibitors.
- Adverse Effects: Diuresis, breast tenderness, lightheadedness, and menstrual spotting.
- Teratogenicity: Risk of feminization of the male fetus (hypospadias, cryptorchidism) through antiandrogenic actions. Women of childbearing potential must use reliable contraception.
3. Oral Isotretinoin & the iPLEDGE REMS Program
Oral isotretinoin is indicated for severe recalcitrant nodulocystic acne, shrinking sebaceous glands by ~90%.
Important
Isotretinoin Teratogenicity & iPLEDGE: Isotretinoin is a potent teratogen carrying a ~30% risk of major congenital anomalies (isotretinoin embryopathy: craniofacial dysmorphism, microtia, cleft palate, thymic aplasia, conotruncal heart defects, hydrocephalus) and a 40% spontaneous abortion rate. Prescribing requires strict federal iPLEDGE REMS compliance:
- Two negative CLIA-certified pregnancy tests prior to starting therapy (the second during the first 5 days of menses).
- Documented use of two concurrent, effective forms of contraception (or continuous abstinence) starting 1 month before, during, and for 1 month post-therapy.
- Monthly negative CLIA pregnancy tests prior to each 30-day prescription dispense.
Rosacea: Subtypes, Comedone Distinction & Management
Rosacea is a chronic facial inflammatory disorder affecting fair-skinned females (Fitzpatrick types I–II) aged 30 to 50.
- Subtypes: Erythematotelangiectatic (flushing, persistent central erythema, telangiectasias), papulopustular (erythema with inflammatory papules/pustules), phymatous (tissue hypertrophy/rhinophyma), and ocular rosacea (blepharitis, conjunctivitis).
- Diagnostic Distinction: The Comedone Rule: The critical clinical feature distinguishing rosacea from acne vulgaris is the ABSENCE OF COMEDONES. The presence of open (blackheads) or closed (whiteheads) comedones confirms acne; rosacea has no comedones.
- Triggers: Ultraviolet radiation, hot beverages, spicy foods, alcohol (especially red wine), extreme temperatures, and emotional stress.
- Management: Trigger avoidance, gentle skin care, daily broad-spectrum mineral sunscreen (zinc oxide/titanium dioxide). First-line topicals include metronidazole 0.75%–1% gel/cream, ivermectin 1% cream (targets Demodex folliculorum mites), and azelaic acid 15%. For severe flares, subantimicrobial-dose oral doxycycline (40 mg daily) provides anti-inflammatory matrix metalloproteinase inhibition without generating resistance.
Specific Dermatoses of Pregnancy: Differential Diagnosis & Fetal Risks
| Condition | Typical Onset & Parity | Clinical Morphology & Distribution | Fetal Morbidity | Diagnostic Workup | First-Line Management |
|---|---|---|---|---|---|
| PUPPP (Polymorphic Eruption of Pregnancy) | Late 3rd trimester (~35 weeks); Primigravidas (75%) | Intensely pruritic urticarial papules and plaques within abdominal striae; STRIKING PERIUMBILICAL SPARING; spreads to thighs. | NONE (benign for mother and fetus). | Clinical diagnosis; normal bile acids and transaminases. | Topical corticosteroids (triamcinolone 0.1%), cool compresses, oral antihistamines (cetirizine). |
| Intrahepatic Cholestasis of Pregnancy (ICP) | Late 2nd or 3rd trimester; Multiparous predilection | Severe nocturnal pruritus WITHOUT primary rash; secondary excoriations; INVOLVES PALMS AND SOLES. | HIGH: Sudden Intrauterine Fetal Demise (IUFD), meconium aspiration, preterm birth. | Total Serum Bile Acids (TBA ≥10 µmol/L); elevated ALT/AST in 60%–80%. | Ursodeoxycholic Acid (UDCA 10–15 mg/kg/day); antenatal surveillance; planned delivery at 36–39 weeks. |
| Atopic Eruption of Pregnancy (AEP) | 1st or 2nd trimester; Any parity | Eczematous lesions on flexural surfaces (neck, antecubital fossae) or prurigo papules. | NONE (benign for fetus). | Clinical diagnosis; elevated serum IgE; atopic history. | Emollients, mild-to-moderate topical corticosteroids. |
| Pemphigoid Gestationis | 2nd or 3rd trimester; Multiparous predilection | Autoimmune subepidermal blistering; urticarial plaques forming tense vesicles/bullae; INVOLVES PERIUMBILICAL REGION. | MODERATE: Fetal growth restriction, preterm delivery, neonatal blistering (5%–10%). | Skin biopsy for Direct Immunofluorescence (DIF): linear C3 deposition at basement membrane. | High-potency topical or oral corticosteroids (prednisone 0.5–1 mg/kg/day); fetal growth scans. |
Intrahepatic Cholestasis of Pregnancy (ICP) Clinical Management
- Clinical Presentation: Intractable pruritus concentrated on the palms of hands and soles of feet, worsening at night, WITHOUT a primary dermatologic rash (only excoriations).
- Bile Acid Stratification: Normal <10 µmol/L; Mild: 10–19 µmol/L; Moderate: 20–99 µmol/L; Severe: ≥100 µmol/L.
- Fetal Hazards: Toxic bile acids induce fetal cardiomyocyte arrhythmias and placental vasoconstriction. Risk of sudden stillbirth increases exponentially when TBA ≥100 µmol/L (3% to 5% risk).
- Delivery Timing (SMFM / ACOG Guidelines):
- TBA ≥100 µmol/L: Deliver at 36 0/7 weeks gestation (or upon diagnosis if later).
- TBA 40 to 99 µmol/L: Deliver at 36 0/7 to 39 0/7 weeks, favoring the earlier part of the window (SMFM).
- TBA 10 to 39 µmol/L: Deliver at 36 0/7 to 39 0/7 weeks gestation.
- Medical therapy: Ursodeoxycholic Acid (UDCA 10 to 15 mg/kg/day) lowers bile acids and relieves pruritus.
Cutaneous Melanoma Screening: ABCDE Criteria & Biopsy Standards
Cutaneous melanoma is one of the most common malignancies in reproductive-age women and during pregnancy (~8% of gestational cancers). Pregnancy does not alter stage-for-stage survival, but delays cause thicker lesions at diagnosis.
The ABCDE Screening Criteria
- A - Asymmetry: One half does not match the other.
- B - Border Irregularity: Notched, scalloped, or poorly circumscribed margins.
- C - Color Variation: Variegated shades of brown, black, blue, red, or white.
- D - Diameter: Greater than 6 mm (standard pencil eraser).
- E - Evolving: Dynamic change in size, shape, surface contour, elevation, or color, or new focal bleeding, itching, or crusting.
- The "Ugly Duckling" Sign: A pigmented lesion that looks visibly distinct from all other nevi.
Biopsy Standards & Breslow Microstaging
Pregnancy is NEVER a contraindication to immediate biopsy; local anesthesia with 1% lidocaine with epinephrine is safe.
Note
Mandatory Biopsy Technique: Perform a full-thickness excisional biopsy with 1 to 3 mm narrow margins into subcutaneous fat. Superficial shave biopsy is strictly contraindicated for suspicious pigmented lesions because it transects the base, compromising histological measurement of Breslow depth (vertical tumor thickness in millimeters). Breslow depth is the single most important prognostic indicator, dictating surgical margins, sentinel lymph node biopsy, and survival.
A 29-year-old female presents to the clinic with persistent inflammatory papules and painful nodules along her mandibular jawline and chin that flare cyclically 7 days prior to each menstrual period. She has tried topical tretinoin 0.05% and benzoyl peroxide 5% wash for 6 months with minimal improvement. She is sexually active with a male partner and currently uses a copper intrauterine device for contraception. The clinician recommends initiating oral spironolactone 50 mg daily. Which counseling point is essential regarding this medication?
Spironolactone has no teratogenic potential and can be safely continued if an accidental pregnancy occurs.
Spironolactone's antiandrogen effect can feminize a male fetus, so reliable contraception is required during therapy.
Serum calcium must be monitored every 2 weeks because spironolactone frequently causes severe hypercalcemia.
The medication acts by permanently destroying cutaneous sebaceous glands within 4 weeks of therapy.
A 24-year-old primigravida at 36 weeks gestation presents with intense abdominal itching that began 4 days ago. Physical examination reveals erythematous urticarial papules and confluent plaques clustered densely within her abdominal striae distensae. There is striking periumbilical sparing with a 2-cm ring of normal, uninvolved skin surrounding her umbilicus. Her palms, soles, and face are completely clear of lesions. Laboratory testing reveals normal liver transaminases (AST 22 U/L, ALT 18 U/L) and a fasting total serum bile acid level of 4 µmol/L (normal <10 µmol/L). What is the diagnosis and appropriate management plan for this patient?
Intrahepatic cholestasis of pregnancy; start ursodeoxycholic acid and schedule delivery at 36 weeks.
Pemphigoid gestationis; obtain an urgent direct immunofluorescence skin biopsy and initiate high-dose oral prednisone.
Atopic eruption of pregnancy; prescribe systemic corticosteroids and place the patient on strict bed rest.
PUPPP; prescribe topical corticosteroids and antihistamines, and reassure her that the fetus is not at risk.
A 32-year-old multiparous female at 34 weeks gestation presents complaining of severe, intractable generalized itching for the past 10 days that is particularly intense on the palms of her hands and soles of her feet, noticeably worsening at night. Physical examination reveals secondary linear excoriations on her forearms and shins, but no primary erythema, papules, plaques, or vesicles. Serum laboratory evaluation reveals: AST 148 U/L, ALT 192 U/L, and a total serum bile acid level of 118 µmol/L. What is the diagnosis, the primary fetal risk, and the evidence-based management strategy?
Severe ICP with risk of sudden stillbirth; start ursodiol, begin antenatal testing, and plan delivery at 36 0/7 weeks.
Benign pruritus gravidarum; reassure the patient that no fetal risk exists and recommend over-the-counter calamine lotion until spontaneous labor at term.
Acute fatty liver of pregnancy; immediately admit to the intensive care unit and perform an emergency cesarean section within 2 hours.
Pemphigoid gestationis; initiate oral hydroxychloroquine and allow the pregnancy to continue expectantly until 41 weeks gestation.
Sections you finish are checked off in the contents.